The six month chart illustrates the breach of support at $7.00 in September of 2011 and what looks like a death cross forming.
What is apparent on this chart is that there is resistance at $10.50 and that there is a death cross that has formed.
If you are comfortable with the risk associated with a microcap company then I would say that AHG is on the verge of moving higher.
Given the selling momentum we may have to retest the lows at $4.60 before we get some buying conviction.
The company is expected to report its Q3 results on November 30, 2010 so circle that date as a flex point that will confirm the advance .. or not.
It’s clear that Lampert will squeeze this pip until it squeaks. If you think that getting a return of capital through a special dividend is worth the loss of capital as the stock declines then fill you boots.
Looking at the value of the stock since the announcement of the merger with Valeant Pharmaceuticals International (VRX TSX) I think the short term good news is already baked into this pie and its about execution of their plan as we go forward.
